Alphamab pre-markets Hong Kong IPO, eyes $1bn valuation

Jonathan Breen

November 18, 2019 07:30 AM

Cancer_cell_29March2017_Fotolia_230x150

Alphamab Oncology, a Chinese biopharmaceutical company, kicked off pre-deal investor education for a potential $250m IPO on Monday after gaining approval to list from the Hong Kong Stock Exchange.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

CITIC Securities Equity IPOs Equity China Jefferies LLC Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia